Quinnova Pharmaceuticals, Inc. Announces Appointment of Senior Vice President of Research & Development
Quinnova Pharmaceuticals, Inc. announced today the appointment of Dr. Christopher Hensby as Senior Vice President Research & Development. Dr. Hensby will assume his new post starting in October of 2008.
Dr. Hensby is a graduate BSc. in Pharmacology from Kings College, London and researched his PhD at Edinburgh University. He began his career in Dermatology in 1975 when he joined Professor Malcolm Greaves at the Institute of Dermatology, St John’s Hospital, London, where he established a new department of Skin Pharmacology. In 1977, he joined Sir Colin Dollery at the Royal Postgraduate Medical School, London University, in the department of Clinical Pharmacology, to continue his research into inflammatory disorders.
Dr. Hensby spent 22 years with Galderma, ultimately in the position of Vice President of World-Wide Regulatory Affairs. While at Galderma, he was intimately involved in the discovery, development, and registration of products for the treatment of acne, eczema, psoriasis and fungal infections including onychomycosis. Most recently as Vice President of R&D and Regulatory Affairs for IVREA Pharmaceuticals, Inc. he successfully developed new technologies for the delivery of active ingredients. Throughout his career Dr. Hensby has striven to provide new, novel, safe and effective therapies for the topical treatment of a wide variety of diseases associated with skin, hair and nail disorders. In response to his appointment Dr. Hensby said, “This is one of the most exciting opportunities and challenges that I have ever had. I am very excited to be joining a young company with some truly innovative technologies and enormous potential. The mix of a great management team with vision, the potential of these proprietary technologies and my experience convinced me that at QUINNOVA we can develop new, innovative, safe and efficacious therapies for many of the unmet needs of diseases of the skin, nail and hair. Quinnova’s existing pipeline of products and future developments will demonstrate in the next few years the passion to bring these to the market place. The company has a very experienced group of scientific advisors and is backed by several long term investors who convinced me that my future is with QUINNOVA.”
“We are extremely pleased to have another leader of Chris’s caliber join the Quinnova management team,” said Jeffrey Day, President & CEO. “He brings expertise both in the development of products in Dermatology and Podiatry markets plus compliance in International Clinical and Regulatory Affairs.”
About Quinnova Pharmaceuticals, Inc.
Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative topical drug delivery platforms. For more information, please visit www.quinnova.com.